Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers

Journal of Controlled Release

Volumn 80, Issue 1-3, 2002, Pages 283-294

  Opanasopit, Praneet ^a   Sakai, Megumi ^a   Nishikawa, Makiya ^a   Kawakami, Shigeru ^b   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Kupffer cells; Mannose receptor; Mannosylated liposome; Muramyl dipeptide; Tumor metastasis

Indexed keywords

IMMUNOMODULATING AGENT; LIPOSOME; MANNOSE; MANNOSE RECEPTOR; MURAMYL DIPEPTIDE; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; EXPERIMENTAL MODEL; LIVER; LIVER METASTASIS; MOUSE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; LIPOSOMES; LIVER; LIVER NEOPLASMS; MALE; MANNOSE; MICE; SERUM ALBUMIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037161342     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00006-8     Document Type: Article

References (43)

1. Metastatic liver tumors
2. Resection of hepatic metastases from colorectal cancer. Biologic perspective
3. Early events of hepatic metastasis formation in mice: Role of Kupffer and NK-cells in natural and interferon-gamma-stimulated defense
4. Role of KC in arresting circulating tumor cells and controlling metastatic growth in the liver
5. An electron microscopy study of KC in livers of mice having Friend erythroleukemia hepatic metastases
6. Kupffer cells and liver metastasis. Optimization and limitation of activation of tumoricidal activity
7. Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide
8. Rapid elimination of a synthetic adjuvant peptide from the circulation after systemic administration and absence of detectable natural muramyl peptides in normal serum at current analytical limits
9. Therapy of murine liver metastases by administration of MDP encapsulated in liposomes
10. Stimulation of Kupffer cell tumoricidal activity by liposomal muramyl dipeptides
11. Macrophage activation by MDP bound to neoglycoproteins: Metastasis eradication in mice
12. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: The role of cytokines
13. Targeting of muramyl dipeptide to macrophages by gelatin conjugation to enhance their in vivo antitumor activity
14. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens
15. Inhibitory effect of liposomal MDP-Lys on lung metastasis of transplantable osteosarcoma in hamster
16. Scavenger receptor-mediated delivery of muramyl dipeptide activates antitumor efficacy of macrophages by enhanced secretion of tumor-suppressive cytokines
17. Mannose-mediated targeted immunoadjuvant action of liposomes
18. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-γ antibody
19. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes
20. The C-type lectin superfamily in the immune system
21. Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice
22. Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice
23. Pharmacokinetic analysis of scavenger receptor-mediated uptake of anionized proteins in the isolated perfused rat liver
24. The binding and processing of mannose-bovine serum albumin derivatives by rabbit alveolar macrophages. Effect of the sugar density
25. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived β-glucocerebrosidase: Implication for clinical efficacy in treatment of Gaucher disease
26. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis
27. Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications
28. Macrophages as targets for drug delivery
29. Virosomes: Evolution of the liposome as a targeted drug delivery system
30. Design of polymeric prodrugs of prostaglandin E(1) having galactose residue for hepatocyte targeting
31. Anticancer therapy using glucuronate modified long-circulating liposomes
32. Involvement of serum mannan binding proteins and mannose receptors in uptake of mannosylated liposomes by macrophages
33. Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor
34. In vivo recognition of mannosylated proteins by hepatic mannose receptors and mannan-binding protein
35. Neo-mannosylated liposomes: Synthesis and interaction with mouse Kupffer cells and resident peritoneal macrophages
36. Mannose receptor
37. Long-circulating liposomes
38. Mechanisms of tumor metastasis: Cell biological aspects and clinical implications
39. The effect of Kupffer cell stimulation or depression on the development of liver metastases in the rat
40. Tumor-associated macrophages (TAMS): Disordered function, immune suppression and progressive tumor growth
41. Muramyl dipeptide stimulation of particle clearance in several animal species
42. Liposome disposition in vivo: Effects of pre-dosing with liposomes
43. Potential value of cetylmannoside-modified liposomes as carriers of macrophage activators to human blood monocytes